Automated Cardiac Channel Panel Screening

Over-dependence on the hERG assay as a preclinical cardiac risk indicator can terminate development of potentially useful compounds that non-selectively block hERG and other compensatory channels. Conversely, some compounds may pose a safety risk by prolonging repolarization via interactions with non-hERG cardiac channels.

Cambridge Bioscience offers access to cardiac ion channel panel screening services from ChanTest. Utilising the PatchXpress® 7000A, QPatch (FASTPatch® Assay) or IonWorks® Quattro™/Barracuda™ (ScreenPatch® Assay), these assays enable the screening of cardiac toxicity and selective profiling of cardiac ion channels using either automated or manual patch clamp platforms.

Features of this Assay
• Complements S7B integrated cardiac risk assessment
• Provides mechanistic interpretation
• Predicts proarrhythmia potential
• Fully validated by expert electrophysiologists

Optional Assays Available
The following assays can be added to the standard project:
• Dose solution analysis – GLP & non-GLP
• Use-dependence analysis
• Temperature-dependence analysis

Additional Options Available
The following features can be added to the standard project:
• Additional copies of final report
• Copies of solution worksheets & data-collection forms
• Integrated risk assessment summary – dose-response, repolarization and in vivo data compiled in one report

Request A No Obligation Quote
To discuss a automated patch clamp cardiac ion channel panel screening project, please contact our experienced team by Clicking Here